Ciprofloxacin, in the fluoroquinlolone class of antibiotics, has been studied for its safety and effectiveness as an anti-fibrotic medication for lung and skin fibrosis in systemic scleroderma.
Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. Int J Mol Med. 2012 Dec; 30(6): 1473–1480. Published online 2012 Oct 5. doi: 10.3892/ijmm.2012.1150
Multi-center clinical trial concludes sufficient evidence to support the use of ciprofloxacin to treat lung and skin fibrosis in systemic scleroderma. This double blind randomized clinical trial carried out over a six month period, published in the International Journal of Molecular Medicine in August 2012, demonstrated the safety and effectiveness of the antibiotic, ciprofloxacin, a broad-spectrum antibiotic of the fluoroquinolone class, as providing significant antifibrotic actions in systemic scleroderma dermal and lung fibroblasts.
Study abstract unavailable for the following study, but the full study may be available for purchase from the British Journal of Rheumatology upon subscription to the journal.
Regression of skin changes in a patient with systemic sclerosis following treatment for bacterial overgrowth with ciprofloxacin. Br J Rheumatol. 1998 Jun;37(6):696.